A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
ApexOnco Front Page
Recent articles
So who else could be interested in the oestrogen degrader?
Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.
DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.
The Breakwater study hits on overall survival with "unprecedented" data.
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
The combined company's MALT1 inhibitor has started phase 1.
